CYOE.OB

[la-onda]

1)
Profile:
CytoCore, Inc., a life sciences company, designs, develops, and commercializes the screening systems to assist in the early detection of cancer. The company is focusing on the e2 cervical cell collection device, and the design and development of its various cancer screening systems for cancer and cancer-related diseases. It is developing InPath System to provide a noninvasive screening test for the detection of endometrial and uterine cancer and to enhance the cervical cancer screening process performed in laboratories. InPath System is a combination of protein antibodies, such as the Cocktail-CVX, and Cocktail-GCI and others, which allow the system to detect and highlight abnormal cancerous cells. It includes the e2 Collector, an approved sample collection device to replace the spatula and brush used to collect patient cytology samples; the Automated Image Proteomic System or AIPS workstation image analysis for automated slide screening of the P2X7 genetic biomarker from cytological and histological specimens; and a drug delivery system consisting of an applicator handle, which is the further development of e2 Collector handle, and drug-delivery modality in the form of a patch that provides a timed release of a therapeutic agent directly to the surface of the cervix. The company's products would be used in laboratory, clinic, or doctor's office. CytoCore was formerly known as Molecular Diagnostics, Inc. and changed its name to CytoCore, Inc. in 2006. The company is headquartered in Chicago, Illinois.

2)
CytoCore Announces Additional Investment by Two Principal Investors
Monday February 4, 9:00 am ET

CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYOE - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today that Chairman of the Board, Daniel Burns and CEO, Robert McCullough Jr. have recently invested $600,000 and $200,000 respectively in the company. McCullough and Burns filed a Form 4 and Burns additionally filed a Form 3, with the SEC, which details the terms of their individual investments. Both Burns and McCullough have helped fund the Company during its recent turn-around and collectively own approximately 10% of CytoCore's common shares outstanding.
"The proceeds from our investment will be used to assist in the scale up of SoftPAP™ manufacturing capacity to meet expected market demand and growth prospects in 2008 and 2009. To date, we have received approximately $10 million in guaranteed orders for 2008 for the SoftPAP device and have initiated shipments to European distributors. We believe our investment illustrates our commitment to generating shareholder returns for our investors, as well as our confidence in the strategy we are implementing to generate those returns," said Mr. Burns.

3)
very interesting chart imo:

[Stocky2000]

I bought shares yesterday;  nice news today...does it go up 10-20% ??

FDA Approves CytoCore's SoftPAP(TM) Cervical Cell Collector
Tuesday February 5, 6:30 am ET


CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYOE - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today that the U.S. Food and Drug Administration has approved the company's 510(k) submission to sell CytoCore's SoftPAP™ cervical cell collector. The SoftPAP collects more comprehensive and complete cervical cell specimens for Pap testing.
ADVERTISEMENT


"CytoCore's SoftPAP™ cervical cell collector is a significant advance in women's health," says Robert McCullough, Jr., CytoCore's CEO. "Each year, over 2 million American women are told that their Pap test was negative when, in fact, they have early stage cervical cancer. These false negatives are frequently caused by an inadequate or incomplete sample of cervical cells. SoftPAP collects complete specimens from the cervical canal, the cervical surface and the transition zone simultaneously. There is evidence that the use of SoftPAP significantly reduces the rate of false negative Pap tests leading to earlier treatment of cervical cancer."

"Studies also demonstrate that the most common adverse events that occur during the collection of the specimen are virtually eliminated with the SoftPAP," according to Dr. Richard Domanik, President and COO. "Studies involving more than 400 cervical cell collections show a 95% reduction in bleeding and spotting which are the most frequently reported adverse events associated with collection of specimens for Pap testing."

"FDA clearance enables us to become a truly global company," says Dan McMahon, Director of Marketing. "We have been selling SoftPAP in Europe for the past few months and are negotiating distribution agreements in Latin America as well. We are in the final stages of completing the North American distribution organization and expect to be able to launch the product in the United States by the end of the first quarter."